958297-44-4

Basic information

• Product Name: tert-butyl 3-(4-fluorophenyl)-3-hydroxyazetidine-1-carboxylate
• Synonyms: tert-butyl 3-(4-fluorophenyl)-3-hydroxyazetidine-1-carboxylate
• CAS NO: 958297-44-4
• Molecular Weight: 267.3
• Mol File: 958297-44-4.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: tert-butyl 3-(4-fluorophenyl)-3-hydroxyazetidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-(4-fluorophenyl)-3-hydroxyazetidine-1-carboxylate(958297-44-4)
• EPA Substance Registry System: tert-butyl 3-(4-fluorophenyl)-3-hydroxyazetidine-1-carboxylate(958297-44-4)

Safety Data

• Hazardous Substances Data: 958297-44-4(Hazardous Substances Data)

Upstream product

• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 352-13-6 4-flourophenylmagnesium bromide 

Downstream Products

• 877319-43-2 tert-butyl (2-(4-fluorophenyl)-2-oxoethyl)carbamate 
• 1225439-03-1 3-butyryloxy-3-(4-fluorophenyl)-1-(tert-butoxycarbonyl)azetidine 

Relevant articles and documents

AZETIDINE DERIVATIVE, AND PRODRUG THEREOF

An object of the present invention is to provide a compound useful as a therapeutic or prophylactic drug for a disease involving the immune system, by suppressing a function of immune cells by suppressing proliferation of activated T cells or suppressing production of interferon alpha (IFN-α) by activated plasmacytoid dendritic cells (pDC), particularly an autoimmune disease such as systemic lupus erythematosus (SLE) and lupus nephritis in SLE patients. The present invention provides a compound represented by general formula (I) : [wherein X, R1, R2, R3, R4, R5 and R6 are as described in the description], or a pharmaceutically acceptable salt thereof.

SUBSTITUTED PYRROLO TRIAZINE CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN EP3 RECEPTOR ANTAGONISTS

The invention relates to substituted pyrrole triazine carboxamide derivatives of formula (I) and to processes for their preparation, and also /to their use for preparing medicaments for the treatment and/ or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.

Synthesis of Simple 3,3-Diarylazetidines from N-Boc-3-arylazetidinols Using Friedel-Crafts Arylation Conditions

A synthesis of 3,3-diarylazetidines from N-Boc-3-aryl-3-azetidinols using Friedel-Crafts arylation conditions with AlCl3 is described. A series of substituted diarylazetidines were readily prepared and isolated as the oxalate salts in high yield and high